UPCC 01617: A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic Melanoma

Age
99 years or below
Gender
All
participants needed
10
Location
1
UPCC 01617: A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic Melanoma

Brief description of study

Request for collaborative review: WIRB serving as IRB of record.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Cancer', 'Non Small Cell Lung Cancer Metastatic', 'Metastatic Melanoma', 'Neoplasm of Lung', 'Melanoma
  • Age: 99 years or below
  • Gender: All
Updated on 04 Aug 2024. Study ID: 827441
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research